NMN vs NAD+: Precursor and Coenzyme Compared

NMN and NAD+ are related as precursor and product. Nicotinamide mononucleotide is a single nucleotide, about half the size of NAD+. Adding an adenine-containing nucleotide converts NMN into NAD+, the coenzyme that cells actually use. Most comparisons online confuse the two or treat them as interchangeable; they are not.

For laboratory research use only. The compounds discussed are not approved for human or veterinary use and are not drugs, foods or cosmetics. This article summarises published research and is not medical advice.

Key points

NMN: 334.2 g/mol, mononucleotide. NAD+: 663.4 g/mol, dinucleotide.
NMN → NAD+ requires an enzymatic step (NMN adenylyltransferases, NMNATs).
NMN availability is described as a rate-limiting factor in mammalian NAD+ biosynthesis.
A 10-week human trial of NMN reported improved muscle insulin sensitivity in a specific population.
Neither is a peptide.

Side-by-side

	NMN	NAD+
Full name	Nicotinamide mononucleotide	Nicotinamide adenine dinucleotide
Formula	C₁₁H₁₅N₂O₈P	C₂₁H₂₇N₇O₁₄P₂
Molecular weight	334.2 g/mol	663.4 g/mol
Components	Nicotinamide + ribose + 1 phosphate	NMN + AMP (adenine, ribose, phosphate)
Role	Precursor	Active coenzyme
Converted by	NMNAT enzymes, to NAD+	Used by dehydrogenases, sirtuins, PARPs, CD38

Structurally, NAD+ is literally NMN joined to AMP through a pyrophosphate bridge. That is why the mass of NAD+ is close to, but not exactly, twice that of NMN.

Why precursors are studied at all

If NAD+ is the active molecule, why work with precursors? Two reasons appear in the literature. First, NAD+ is a large, charged dinucleotide, and cells regulate its levels through biosynthesis and salvage rather than by importing it intact. Second, NMN availability has been described as a rate-limiting factor in mammalian NAD+ biosynthesis (Yoshino et al., 2021). Reviews of NAD-boosting molecules cover precursors including NMN and nicotinamide riboside, and the question of which routes most effectively raise tissue NAD+ (Rajman et al., 2018; Verdin, 2015).

The human NMN trial

A randomised, placebo-controlled, double-blind trial ran for 10 weeks in postmenopausal women with prediabetes who were overweight or obese (Yoshino et al., 2021).

Measure	Result
Insulin-stimulated glucose disposal (hyperinsulinaemic-euglycaemic clamp)	Increased after NMN; unchanged after placebo
Skeletal muscle insulin signalling (AKT and mTOR phosphorylation)	Increased after NMN
Muscle remodelling genes (e.g. PDGF receptor β)	Up-regulated
Trial registration	NCT03151239

This is one trial in a narrowly defined group, and the paper attracted published comments and discussion, which is normal for a result of this kind. It should not be generalised to other populations or to NAD+ itself.

Practical differences in the lab

Aspect	NMN	NAD+
Size and charge	Smaller, one phosphate	Larger, two phosphates
UV detection	~260 nm	~260 nm (NADH also 340 nm)
Typical solution stability	Sensitive to pH and temperature	Most stable in Tris; less so in phosphate or HEPES
In cell assays	Requires conversion to act	Active directly in cell-free systems

For cell-free biocatalysis, buffer choice is consequential: in a 43-day study, NAD+ and NADH were much more stable in Tris than in sodium phosphate or HEPES, and a mild temperature increase mattered significantly (Wolfe et al., 2024). The same principles are a reasonable starting point for NMN solutions, though the study measured the dinucleotide cofactors.

Choosing between them for research

Studying enzyme activity in vitro (dehydrogenases, sirtuins, PARPs): NAD+ is the direct substrate.
Studying biosynthesis or salvage pathways: NMN and other precursors are the relevant tools.
Measuring cellular NAD+ levels after precursor exposure: both, with an assay that distinguishes them.

Our NAD+ research material is supplied in 100 mg, 500 mg and 1000 mg vials. For background, see what is NAD+?, and for reconstitution, reconstituting NAD+.

A note on naming

Catalogue listings sometimes use “NMN” and “NAD+” loosely, and occasionally describe both as peptides. Neither is a peptide. When ordering or citing material, check the molecular weight on the certificate of analysis: 334.2 g/mol indicates NMN, 663.4 g/mol indicates NAD+, and 665.4 g/mol indicates NADH. The difference is large enough that mass spectrometry resolves it without ambiguity.

Open questions

How much does oral or parenteral NMN raise NAD+ in specific human tissues?
Do NMN and nicotinamide riboside differ meaningfully in effectiveness?
Does the insulin-sensitivity finding replicate in other populations and over longer periods?

Related research

Frequently asked questions

What is the difference between NMN and NAD+?

NMN (nicotinamide mononucleotide) is a mononucleotide of about 334 g/mol. NAD+ is a dinucleotide of about 663 g/mol. NMN is a direct precursor: adding an adenine-containing nucleotide to NMN produces NAD+.

Is NMN the same as NAD?

No. They are different molecules, related as precursor and product. NMN must be converted enzymatically before it can act as the coenzyme.

Which is better, NMN or NAD+?

That depends on the research question. NMN is studied as a way to raise NAD+ levels; NAD+ itself is the active coenzyme. Neither is universally better, and direct comparative human studies are limited.

Has NMN been tested in humans?

Yes. A 10-week randomised, placebo-controlled trial in postmenopausal women with prediabetes who were overweight or obese reported increased insulin-stimulated glucose disposal and muscle insulin signalling after NMN.

Is NMN a peptide?

No. Like NAD+, NMN is a nucleotide and contains no amino acids.

References

Covarrubias AJ, et al. NAD(+) metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021. PMID: 33353981 https://pubmed.ncbi.nlm.nih.gov/33353981/
Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021. PMID: 33888596 https://pubmed.ncbi.nlm.nih.gov/33888596/
Rajman L, et al. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018. PMID: 29514064 https://pubmed.ncbi.nlm.nih.gov/29514064/
Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015. PMID: 26785480 https://pubmed.ncbi.nlm.nih.gov/26785480/
Wolfe KD, et al. Long-Term Stability of Nicotinamide Cofactors in Common Aqueous Buffers: Implications for Cell-Free Biocatalysis. Molecules. 2024. PMID: 39598842 https://pubmed.ncbi.nlm.nih.gov/39598842/
PubChem Compound Summary for CID 14180, Nicotinamide mononucleotide. National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/14180